Assenagon Asset Management
PRTK

Assenagon Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Assenagon Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-368,240
Closed -$935K – 1504
2023
Q1 		$935K Buy
368,240
+236,976
+181% +$468K ﹤0.01% 1065
2022
Q4 		$245K Sell
131,264
-83,141
-39% -$207K ﹤0.01% 1290
2022
Q3 		$551K Buy
214,405
+120,393
+128% +$300K ﹤0.01% 1087
2022
Q2 		$181K Buy
+94,012
New +$205K ﹤0.01% 1390

Other funds holding PRTK

NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Assenagon Asset Management's PRTK Position: Q2 2023 in Review

Assenagon Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2023, closing a stake of 368,240 shares — an estimated $935K sold.

Assenagon Asset Management first reported a position in PRTK in Q2 2022 and held it in 4 quarters. The position peaked at $935K in Q1 2023. 66 funds tracked by Wall St. Rank hold PRTK as of Q2 2023.

  • Assenagon Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Assenagon Asset Management sold 368,240 Paratek Pharmaceuticals, Inc. shares in Q2 2023, an estimated $935K.
  • Assenagon Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2022 and held it in 4 quarters.
  • Assenagon Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $935K in Q1 2023.
  • 66 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2023.

Based on Assenagon Asset Management's 13F filing for Q2 2023, filed 25 Jul 2023.